29668-62-0

Basic information

• Product Name: Methyl 2-(diethylphosphono)propanoate
• Synonyms: Methyl 2-(diethylphosphono)propanoate;Methyl Diethyl 2-Phosphonopropionate;Methyl 2-diethoxyphosphorylpropanoate
• CAS NO: 29668-62-0
• Molecular Formula: C₈H₁₇O₅P
• Molecular Weight: 224.191341
• Mol File: 29668-62-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 2-(diethylphosphono)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(diethylphosphono)propanoate(29668-62-0)
• EPA Substance Registry System: Methyl 2-(diethylphosphono)propanoate(29668-62-0)

Safety Data

• Hazardous Substances Data: 29668-62-0(Hazardous Substances Data)

Upstream product

• 5445-17-0 Methyl 2-bromopropionate 
• 122-52-1 triethyl phosphite 
• 1067-74-9 Methyl diethylphosphonoacetate 
• 74-88-4 methyl iodide 
• 121-45-9 phosphorous acid trimethyl ester 

Downstream Products

• 5962-41-4 2-Phosphono-propionsaeure 
• 22946-43-6 (E)-methyl-2-methyl-3-phenylacrylate 
• 89996-94-1 methyl 2-methyl-5-phenyl-2,4-pentadienoate 
• 72079-83-5 methyl 4,6-O-benzylidene-2,3-dideoxy-2,3-C--α-D-mannopyranoside 
• 220654-86-4 (E)-methyl 2-methyl-3-(4-(trifluoromethyl)phenyl)acrylate 
• 103359-61-1 Methyl E-2-methyl-4'-fluorocinnamate 
• 89812-66-8 (2E,4E)-5-(4-Chloro-phenyl)-2-methyl-penta-2,4-dienoic acid methyl ester 
• 89812-64-6 (2E,4E)-2-Methyl-5-p-tolyl-penta-2,4-dienoic acid methyl ester 
• 20414-93-1 E-methyl-2-phenyl-5-pentadien-2,4-oate de methyle 
• 139539-80-3 methyl (Z)-2-methyl-2-hexenoate 
• 16493-96-2 (E)-2-methyl-2-hexenoic acid, methyl ester 

Relevant articles and documents

Design, synthesis and SAR study of novel sulfonylureas containing an alkenyl moiety

A series of sulfonylurea compounds was designed and synthesized via introducing an alkenyl moiety into the aryl-5 position and most title compounds exhibited enhanced antifungal activities and limited herbicidal activities compared with chlorsulfuron. Then, a CoMSIA calculation for antifungal activities was carried out to establish a 3D-QSAR model in which a cross-validated q2 of 0.585 and a correlation coefficient r2 of 0.989 were obtained. The derived model revealed that hydrophobic and electrostatic fields were the two most important factors for antifungal activity. Structure optimization was performed according to the CoMSIA model and compound 9z was found to be as potent as chlorothalonil in vitro against C. cornigerum, the pathogen of the wheat sharp eyespot disease. In order to study the fungicidal mechanism, 9z was successfully docked into yeast AHAS using a flexible molecular docking method and the resulting binding pattern was similar to that of chlorimuron-ethyl, indicating that the antifungal activity of compounds 9 was probably due to the inhibition of fungal AHAS.

COMPOUNDS USEFUL AS MODULATORS OF TRPM8

The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formulae (Ia), (Ib) and (Ic), and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations.

HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE

Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE

Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to compounds of Formula (I) as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.